



(FW)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Asa Rosenquist et al.

**Examiner:** Ha, Julie

**Serial No.:** 10/572,418

**Art Unit:** 1654

**Filed:** March 17, 2006

**Docket:** 19555

**For:** HCV-NS-3 SERINE PROTEASE  
INHIBITORS

**Dated:** June 17, 2008

**Confirmation No.:** 7910

Mail Stop: Amendment  
Commissioner for Patent  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:


In accordance with 37 C.F.R. §§1.97 and 1.98, applicants have listed on the attached Form PTO-1449 art to be made of record in the above-identified case.

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mailstop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 17, 2008


Dated: June 17, 2008

  
Mark J. Cohen

Applicants respectfully request that the information cited in this Information Disclosure Statement be made of record herein. Consideration of the information is respectfully requested since the art provided may be material to the examination of the present application as defined in 37 CFR §1.56. It should also be understood that the information listed on the attached PTO 1449 form should not be construed as prior art. There are items listed therein which may be relevant to the examination of the present application although not considered prior art, e.g. U.S. Patent Application S/N 10/572,349 filed March 17, 2006 and U.S. Patent Application S/N 10/632,102 filed January 10, 2007.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. §1.97(b), no statement or fee is required.

Respectfully submitted,



Mark J. Cohen  
Registration No. 32,211

Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343

MJC:htj

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
**19555**

In Re Application Of **Asa Rosenquist, et al.**

Application No.

Filing Date

Examiner

Customer No.

Group Art Unit

Confirmation No.

**10/572,418**

**March 17, 2006**

**Julie Ha**

**23389**

**1654**

**7910**

Title: **HCV NS-3 SERINE PROTEASE INHIBITORS**

Address to:

**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
19555

In Re Application of: Sa Rosenquist, et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/572,418	March 17, 2006	Julie Ha	23389	1654	7910

Title: **HCV NS-3 SERINE PROTEASE INHIBITORS**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

June 17, 2008

\_\_\_\_\_  
(Date)


\_\_\_\_\_  
Signature of Person Mailing Correspondence

Mark J. Cohen

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

Dated: June 17, 2008

  
Signature  
Mark J. Cohen, Esq.  
Registration No. 32,211  
Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343

cc: MJC:htj

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

JUN 20 2008

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
19555

In Re Application Of: **Asa Rosenquist, et al.**

Application No.

Filing Date

Examiner

Customer No.

Group Art Unit

Confirmation No.

10/572,418

March 17, 2006

Julie Ha

23389

1654

7910

Title: **HCV NS-3 SERINE PROTEASE INHIBITORS**

Address to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

**OR**

☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
19555

In Re Application of: Asa Rosenquist, et al.

JUN 20 2008

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/572,418	March 17, 2006	Julie Ha	23389	1654	7910

Title: HCV NS-3 SERINE PROTEASE INHIBITORS

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

June 17, 2008

(Date)

Signature of Person Mailing Correspondence

Mark J. Cohen

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

Dated: June 17, 2008

Mark J. Cohen, Esq.  
Registration No. 32,241  
Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343

cc: MJC:htj



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Asa Rosenquist et al.

**Examiner:** Ha, Julie

**Serial No.:** 10/572,418

**Art Unit:** 1654

**Filed:** March 17, 2006

**Docket:** 19555

**For:** HCV-NS-3 SERINE PROTEASE  
INHIBITORS

**Dated:** June 17, 2008

**Confirmation No.:** 7910

Mail Stop: Amendment  
Commissioner for Patent  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:


In accordance with 37 C.F.R. §§1.97 and 1.98, applicants have listed on the attached Form PTO-1449 art to be made of record in the above-identified case.

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mailstop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 17, 2008


**Dated:** June 17, 2008

  
Mark J. Cohen

Applicants respectfully request that the information cited in this Information Disclosure Statement be made of record herein. Consideration of the information is respectfully requested since the art provided may be material to the examination of the present application as defined in 37 CFR §1.56. It should also be understood that the information listed on the attached PTO 1449 form should not be construed as prior art. There are items listed therein which may be relevant to the examination of the present application although not considered prior art, e.g. U.S. Patent Application S/N 10/572,349 filed March 17, 2006 and U.S. Patent Application S/N 10/632,102 filed January 10, 2007.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. §1.97(b), no statement or fee is required.

Respectfully submitted,



Mark J. Cohen  
Registration No. 32,211

Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343


MJC:htj



**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
19555

In Re Application Of: Asa Rosenquist, et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/572,418	March 17, 2006	Julie Ha	23389	1654	7910

Title: HCV NS-3 SERINE PROTEASE INHIBITORS

Address to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);


OR

☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
19555

In Re Application of: Asa Rosenquist, et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/572,418	March 17, 2006	Julie Ha	23389	1654	7910

Title: HCV NS-3 SERINE PROTEASE INHIBITORS

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa
_____ (Date)
_____ Signature
_____ Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on
June 17, 2008 (Date)
_____ Signature of Person Mailing Correspondence
Mark J. Cohen Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

\_\_\_\_\_  
Signature

Dated: June 17, 2008


Mark J. Cohen, Esq.  
Registration No. 32,241  
Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343

cc: MJC:htj

1F2V

**PATENT OFFICE DATE STAMP WILL ACKNOWLEDGE RECEIPT OF:**

1. Response
2. Transmittal of Information Disclosure Statement (in duplicate)
3. Information Disclosure Statement
4. PTO-1449 with References 1-34
5. Certificate of Mailing dated June 17, 2008



Applicant: Asa Rosenquist, et al.  
Serial No.: 10/572,418  
Filed: January 22, 2007  
For: HCV NS-3 SERINE PROTEASE INHIBITORS  
Docket: 19555  
Date: June 17, 2008  
MJC:htj